In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lab21 Ltd.

Division of Novacyt SA

Latest From Lab21 Ltd.

Device/Diagnostics Quarterly Deal Statistics, Q2 2015

At $1.8 billion, Q2 device financing nearly doubled the Q1 total, mainly from an increase in IPOs and early VC rounds, and acquisitions were slightly higher at $4.7 billion. Diagnostics funding also increased to $784 million from Q1's $597 million, and Danaher's monster $13.8 billion buy of life sciences company Pall headlined the second quarter's $15.6 billion total in diagnostics M&A activity.

Medical Device Deals

Lab21 Merges With Cervical Cancer Screening Firm Novacyt

The stock-based reverse takeover gives molecular diagnostics firm Lab21 access to Novacyt’s NovaPrep, a second-generation liquid-based cytology screening platform that competes against Roche and Hologic offerings.

Medical Device Strategy

Medical Device Deals Update, November 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced October-November 2013.

Medical Device

Deals In Depth: October 2013

Eli Lilly agreed to co-promote Pfizer’s anti-NGF tanezumab for $200 million up front plus $350 million in regulatory milestones; private equity firms Avista and Nordic are taking Swiss pharmaco Acino private in a $439 million deal. Both biopharma and device financing increased in October vs. the previous month thanks to strong showings from IPOs and secondary offerings.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Molecular Diagnostics & Genetic Testing
  • Laboratory Testing Services
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Novacyt SA
  • Senior Management
  • Graham Mullis, CEO
    Susan Lowther, CFO
  • Contact Info
  • Lab21 Ltd.
    Phone: (44) 1223 395450
    Park House, Winship Rd.
    Cambridge, CB24 6BQ